IPHYF Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Innate Pharma SA

Watchlist Manager

Watchlist

Price: 1.65 USD

Market Cap: $133.6m

I	Innate Pharma SA OTC:IPHYF	FR
K	Kwesst Micro Systems Inc XTSX:DFSC	CA
I	Innate Pharma SA SWB:IDD	FR
D	Dhunseri Ventures Ltd BSE:523736	IN

Profitability Summary

Innate Pharma SA's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Strong 3Y Average Gross Margin

67%

Declining Gross Margin

93% > 1%

Negative Operating Margin

-1 834%

Negative 3Y Average Operating Margin

-570%

Declining Operating Margin

-33% > -1 834%

Negative Net Margin

-1 765%

Negative 3Y Average Net Margin

-537%

Declining Net Margin

-117% > -1 765%

Negative Free Cash Flow Margin

-1 898%

Negative 3Y Average Free Cash Flow Margin

-478%

Declining Free Cash Flow Margin

-41% > -1 898%

Exceptional ROE

764%

Exceptional 3Y Average ROE

Negative 3Y Average ROIC

-221%

Declining ROIC

-15% > -835%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.